

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Dr. Xu Ming has been appointed as a non-executive director of the Company with effect from 25 October 2024.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Xu Ming (“**Dr. Xu**”) has been appointed as a non-executive director of the Company (“**NED**”) with effect from 25 October 2024.

Dr. Xu, aged 65, has extensive experience in the fields of molecular pharmacology. Dr. Xu had served as the director of the Institute of Molecular Medicine and Therapeutics* (分子藥物與治療研究所) at Central South University (中南大學) in the People’s Republic of China. Dr. Xu had also served as the officer of the China Chronic Disease Research Base* (中國慢病研究基地中心) of the China International Exchange and Promotive Association for Medical and Health Care (中國醫療保健國際交流促進會) from June 2018 to June 2021. In December 2020, Dr. Xu became the president of the Microecology Branch* (微生物分會) of the China Ethnic Medicine Association* (中國民族醫藥協會).

Dr. Xu completed the course of Japanese Medical Science at the Undergraduate Medical Department* (本科醫學系日文醫學專業) of China Medical University (中國醫科大學) and obtained a Bachelor of Medicine in December 1982. He also obtained a degree of Doctor of Philosophy in Medical Science from the Osaka University in Japan in March 1994.

Dr. Xu has entered into an appointment letter with the Company for an initial term of three years commencing from 25 October 2024 and will continue thereafter until terminated by either party serving not less than one month’s written notice to the other party. Pursuant to the appointment letter, Dr. Xu is entitled to a director’s emolument of HK\$120,000 per annum. Such fee is determined by the Board based on the recommendation of the remuneration committee with reference to his experience, responsibilities, workload and time devoted to the Company and will be subject to review by the remuneration committee of the Company from time to time. Save as disclosed above, Dr. Xu is not expected to receive any other remuneration for holding his office as a NED.

* English translation is for identification purpose only

In accordance with the articles of association of the Company, Dr. Xu will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. Dr. Xu will be subject to rotation requirements as contained in the articles of association of the Company and shall retire from office by rotation at least once every three years.

Save as disclosed above, as at the date of this announcement, Dr. Xu (i) does not hold any other position in the Company and other members of the Group; (ii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not possess any other major appointments or professional qualifications; (iv) does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any information which is disclosable nor is/was Dr. Xu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited and there are no other matters concerning Dr. Xu that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Dr. Xu for joining the Board.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 25 October 2024

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; the Non-executive Director are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Ms. Chow Ching Man.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company's website at www.huakangbiomedical.com.